Thomas Smith
Stock Analyst at Leerink Partners
(1.56)
# 3,551
Out of 4,829 analysts
71
Total ratings
20%
Success rate
3.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.38 | +163.16% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.66 | +442.17% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.25 | +460.00% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $5.25 | +452.38% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $10.41 | +274.64% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $3.31 | +685.50% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $0.88 | +1,041.03% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $6.40 | +212.50% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $560.90 | -22.45% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $46.65 | -22.83% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $0.78 | +797.44% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $14.55 | +44.33% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.11 | +243.25% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $6.71 | -10.51% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $4.81 | +24.74% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.99 | +406.74% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $40.18 | -57.69% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $20.17 | +217.30% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.73 | +318.41% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $8.09 | +258.47% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.95 | +781.36% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $0.33 | +3,540.78% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $28.30 | -57.60% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.36 | +129.36% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $2.79 | +14,236.92% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.74 | +482.24% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.38
Upside: +163.16%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.66
Upside: +442.17%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.25
Upside: +460.00%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $5.25
Upside: +452.38%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $10.41
Upside: +274.64%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $3.31
Upside: +685.50%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $0.88
Upside: +1,041.03%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $6.40
Upside: +212.50%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $560.90
Upside: -22.45%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $46.65
Upside: -22.83%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $0.78
Upside: +797.44%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $14.55
Upside: +44.33%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $13.11
Upside: +243.25%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $6.71
Upside: -10.51%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.81
Upside: +24.74%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.99
Upside: +406.74%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $40.18
Upside: -57.69%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $20.17
Upside: +217.30%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.73
Upside: +318.41%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $8.09
Upside: +258.47%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.95
Upside: +781.36%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.33
Upside: +3,540.78%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $28.30
Upside: -57.60%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.36
Upside: +129.36%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $2.79
Upside: +14,236.92%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.74
Upside: +482.24%